APREPITANT AND RIFAMPICIN (RIFAMPIN)

Rifampicin reduced the AUC of aprepitant by 91%, and reduced efficacy would be expected. Fosaprepitant, a prodrug of aprepitant, would be expected to interact similarly.
The UK manufacturer recommends that concurrent use should be avoided.